A Phase 2 interventional study of Setmelanotide and Placebo in Overweight, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-14.
Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,479 studies in Overweight with a site in United States — 273 open to participants now, 400 under way, 69 of them phase 3. Overweight · United States.
Among the 1,479 studies in Overweight with a site in United States, this one is the 742nd largest by enrollment of the 1,365 interventional ones that give a count, is one of 37 that started in 2013, is one of 147 in phase 2, and was the 334th registered.
3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.
Browse Overweight studies →273 of the 1,479 studies in Overweight with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–70
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
University of California, Los Angeles · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,479 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 148 · Phase 2 177 · Phase 3 126 · Phase 4 31
First in 1983; this study’s year is marked. 37 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is close to the median of 78 across 3,132 interventional studies indexed under Overweight.
Median enrollment 85 across the 1,365 interventional studies, 126 across the 112 observational. Of the 1,017 that completed or were terminated, 247 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
380 of 1,479 have an industry lead sponsor. The 10 most frequent:
Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
Rhythm Pharmaceuticals, Inc. has 3 studies filed under Overweight — fewer than ten, so there is no comparison to draw.
157 of the studies in Overweight with a site in United States that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07298915Phase 3University of VirginiaThe Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) | 2026-12 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
Add all 157 to your calendar (.ics) → With an account.
Among the 1,479 studies in Overweight with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of RM-493 on mean percent body weight loss, and other weight loss parameters as well as Pharmacokinetic (PK) profile, and ambulatory blood pressure in obese participants. The study is designed to evaluate the efficacy and tolerability of a single dose of RM-493. The study drug (RM-493 and placebo) will be administered subcutaneously in a blinded fashion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with a history of the following:
Use of prescription medications on a regular basis with the following exceptions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 1 milligram (mg) setmelanotide every day by continuous subcutaneous infusion using the Omnipod insulin pump for a duration of 90 days.
Drug: Setmelanotide
Participants received placebo matching setmelanotide every day by continuous subcutaneous infusion using the Omnipod insulin pump for a duration of 90 days.
Drug: Placebo
Daily subcutaneous infusion
Also known as: RM-493
Daily subcutaneous infusion
Percent Change From Baseline in Body Weight
The mean percent change from baseline in body weight at Day 90 was analyzed.
Time frame: Baseline and Day 90
Change From Baseline in Body Weight
The mean change from baseline in body weight at day 90 was analyzed.
Time frame: Baseline and Day 90
Percentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight
The percentage of participants who lost ≥ 5% of their baseline body weight was analyzed. 95% confidence interval is calculated based on Clopper-Pearson.
Time frame: Baseline up to Day 90
Number of Participants Who Consistently Achieved Targeted Plasma Concentration of ~6 Nanogram Per Milliliter (ng/mL)
Number of Participants Who Consistently Achieved Targeted Plasma Concentration of \~6 ng/mL were reported.
Time frame: Day 1: pre-dose and 2-hours post-infusion, Day 7, 14, 28, 56, and 90
Percentage of Participants With Treatment Emergent Adverse Events
An adverse event (AE) was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An adverse event (also referred to as an adverse experience) could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. A treatment-emergent AE was defined as an AE with an onset date on or after day 1.
Time frame: From first dose of study drug (Day 1) until end of study (Up to 184 days)
Change From Baseline in Ambulatory Blood Pressure Monitoring Parameter (ABPM) - Systolic Blood Pressure
Summary of individual average data at daytime, nighttime and 24 hours was reported.
Time frame: Baseline and Day 28
Change From Baseline in ABPM - Diastolic Blood Pressure
Summary of individual average data at daytime, nighttime and 24 hours was reported.
Time frame: Baseline and Day 28
Change From Baseline in ABPM - Mean Arterial Blood Pressure
Summary of individual average data at daytime, nighttime and 24 hours was reported.
Time frame: Baseline and Day 28
Change From Baseline in ABPM - Heart Rate
Summary of individual average data at daytime, nighttime and 24 hours was reported.
Time frame: Baseline and Day 28
Change From Baseline in ABPM - Pulse Pressure
Summary of individual average data at daytime, nighttime and 24 hours was reported.
Time frame: Baseline and Day 28
Percent Change From Baseline in Body Weight in Severely Obese Participants
The mean percent change from baseline in body weight in severely obese participants at Day 90 was analyzed.
Time frame: Baseline and Day 90
Percentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight in Severely Obese Participants
The percentage of participants who lost ≥ 5% of their baseline body weight loss in severely obese participants was analyzed. 95% confidence interval is calculated based on Clopper-Pearson confidence interval.
Time frame: Baseline up to Day 90
| Milestone | Setmelanotide | Placebo |
|---|---|---|
| Started | 37 | 37 |
| Completed | 22 | 26 |
| Not completed | 15 | 11 |
| Withdrew: Adverse event | 4 | 4 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 8 | 4 |
The mean percent change from baseline in body weight at Day 90 was analyzed.
| Percent change | Setmelanotide | Placebo |
|---|---|---|
| Percent Change From Baseline in Body Weight | -2.0 ± 2.82 | -0.3 ± 2.96 |
The mean change from baseline in body weight at day 90 was analyzed.
| Kilograms | Setmelanotide | Placebo |
|---|---|---|
| Change From Baseline in Body Weight | -2.2 ± 3.39 | -0.3 ± 3.34 |
The percentage of participants who lost ≥ 5% of their baseline body weight was analyzed. 95% confidence interval is calculated based on Clopper-Pearson.
| percentage of participants | Setmelanotide | Placebo |
|---|---|---|
| Percentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight | 9.1 (1.9 to 24.3) | 5.6 (0.7 to 18.7) |
Number of Participants Who Consistently Achieved Targeted Plasma Concentration of \~6 ng/mL were reported.
| Participants | Setmelanotide |
|---|---|
| Number of Participants Who Consistently Achieved Targeted Plasma Concentration of ~6 Nanogram Per Milliliter (ng/mL) | 8 |
An adverse event (AE) was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An adverse event (also referred to as an adverse experience) could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. A treatment-emergent AE was defined as an AE with an onset date on or after day 1.
| percentage of participants | Setmelanotide | Placebo |
|---|---|---|
| Percentage of Participants With Treatment Emergent Adverse Events | 75.7 | 48.7 |
Summary of individual average data at daytime, nighttime and 24 hours was reported.
| millimeter of mercury (mmHg) | Setmelanotide | Placebo |
|---|---|---|
| Daytime individual average | -2.45 ± 14.071 | 1.83 ± 12.200 |
| Night time individual average | -3.26 ± 13.310 | 1.24 ± 10.721 |
| 24 hour (hr) individual average | -2.79 ± 13.174 | 1.61 ± 11.165 |
Summary of individual average data at daytime, nighttime and 24 hours was reported.
| mmHg | Setmelanotide | Placebo |
|---|---|---|
| Daytime individual average | -1.62 ± 9.672 | 1.39 ± 5.591 |
| Night time individual average | -0.96 ± 9.586 | 0.60 ± 5.184 |
| 24 hr individual average | -1.38 ± 9.261 | 1.09 ± 4.977 |
Summary of individual average data at daytime, nighttime and 24 hours was reported.
| mmHg | Setmelanotide | Placebo |
|---|---|---|
| Daytime individual average | -1.27 ± 10.886 | 1.70 ± 8.056 |
| Night time individual average | -2.15 ± 10.589 | 0.86 ± 6.536 |
| 24 hr individual average | -1.65 ± 10.205 | 1.38 ± 7.018 |
Summary of individual average data at daytime, nighttime and 24 hours was reported.
| Beats per minute (BPM) | Setmelanotide | Placebo |
|---|---|---|
| Daytime individual average | 1.44 ± 6.861 | -1.90 ± 8.702 |
| Night time individual average | -0.28 ± 8.293 | 0.05 ± 10.420 |
| 24 hr individual average | 0.70 ± 6.703 | -1.07 ± 8.242 |
Summary of individual average data at daytime, nighttime and 24 hours was reported.
| mmHg | Setmelanotide | Placebo |
|---|---|---|
| Daytime individual average | -0.83 ± 6.320 | 0.44 ± 8.060 |
| Night time individual average | -2.30 ± 6.038 | 0.65 ± 6.820 |
| 24 hr individual average | -1.41 ± 5.655 | 0.52 ± 7.366 |
The mean percent change from baseline in body weight in severely obese participants at Day 90 was analyzed.
| Percent change | Setmelanotide | Placebo |
|---|---|---|
| Percent Change From Baseline in Body Weight in Severely Obese Participants | -2.3 ± 3.34 | -0.7 ± 3.08 |
The percentage of participants who lost ≥ 5% of their baseline body weight loss in severely obese participants was analyzed. 95% confidence interval is calculated based on Clopper-Pearson confidence interval.
| percentage of participants | Setmelanotide | Placebo |
|---|---|---|
| Percentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight in Severely Obese Participants | 11.8 (1.5 to 36.4) | 11.8 (1.5 to 36.4) |
Collected over From first dose of study drug (Day 1) until end of study (Up to 184 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Setmelanotide | 0/37 (0%) | 0/37 (0%) | 28/37 (75.7%) |
| Placebo | 0/37 (0%) | 1/37 (2.7%) | 18/37 (48.6%) |
| Event | Setmelanotide | Placebo |
|---|---|---|
| Biliary dyskinesiaHepatobiliary disorders | 0/37 | 1/37 |
| Event | Setmelanotide | Placebo |
|---|---|---|
| Skin hyperpigmentationSkin and subcutaneous tissue disorders | 9/37 | 0/37 |
| Upper respiratory tract infectionInfections and infestations | 3/37 | 5/37 |
| Skin discolourationSkin and subcutaneous tissue disorders | 5/37 | 0/37 |
| NauseaGastrointestinal disorders | 5/37 | 3/37 |
| Application site pruritusGeneral disorders | 5/37 | 1/37 |
| HeadacheNervous system disorders | 4/37 | 1/37 |
| CellulitisInfections and infestations | 3/37 | 1/37 |
| Decreased appetiteMetabolism and nutrition disorders | 3/37 | 0/37 |
| Ear infectionInfections and infestations | 0/37 | 2/37 |
| UrticariaSkin and subcutaneous tissue disorders | 2/37 | 0/37 |
The Full Analysis Set (FAS) consisted of all randomized participants with both a baseline and at least one post-dose efficacy observation (for at least one efficacy endpoint).
| Age, Continuous(years) | Setmelanotide | Placebo | Total |
|---|---|---|---|
| Mean | 42.0 ± 9.77 | 40.4 ± 11.72 | 41.2 ± 10.74 |
| Sex: Female, Male(Participants) | Setmelanotide | Placebo | Total |
|---|---|---|---|
| Female | 31 | 35 | 66 |
| Male | 6 | 2 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Setmelanotide | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 6 |
| Not Hispanic or Latino | 34 | 33 | 67 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Setmelanotide | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 15 | 16 | 31 |
| White | 21 | 21 | 42 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Body Weight(Kilograms) | Setmelanotide | Placebo | Total |
|---|---|---|---|
| Mean | 113.65 ± 16.074 | 111.20 ± 10.031 | 112.43 ± 13.362 |
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2013 to primary completion in Sep 2013, 8 months.
Results were first posted in Aug 2023, 9 years 10 months after primary completion. A results delay was requested in Nov 2014.
Of 102 industry-sponsored phase 2 interventional studies under Overweight, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 16. This study's 8 months is below that.
Counting every sponsor, half of 148 studies reached it within 13 months; a quarter within 8 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Setmelanotide
Rhythm Pharmaceuticals, Inc. →